{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03086044",
            "orgStudyIdInfo": {
                "id": "2016-P001170"
            },
            "organization": {
                "fullName": "Brigham and Women's Hospital",
                "class": "OTHER"
            },
            "briefTitle": "Transplanting Hepatitis C Positive Organs",
            "officialTitle": "Transplanting Organs From Hepatitis C Positive Donors to Hepatitis C Uninfected Recipients",
            "therapeuticArea": [
                "Other",
                "Gastroenterology"
            ],
            "study": "transplanting-hepatitis-c-positive-organs"
        },
        "statusModule": {
            "statusVerifiedDate": "2022-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2017-03-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2016-09-12",
            "studyFirstSubmitQcDate": "2017-03-21",
            "studyFirstPostDateStruct": {
                "date": "2017-03-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2022-10-10",
            "lastUpdatePostDateStruct": {
                "date": "2022-10-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Lindsey R. Baden, MD",
                "investigatorTitle": "Associate Professor at Harvard Medical School",
                "investigatorAffiliation": "Brigham and Women's Hospital"
            },
            "leadSponsor": {
                "name": "Brigham and Women's Hospital",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label, pilot safety and efficacy trial for adults who are active on the heart, lung, or kidney transplantation lists and are eligible to receive an organ from an increased risk donor who has evidence of active or prior hepatitis C infection (HCV).",
            "detailedDescription": "This is an open label pilot study transplanting organs from Hepatitis C positive donors into HCV uninfected recipients at Brigham and Women's Hospital. Heart, lung and kidney transplant participants will be stratified into two different study arms depending on whether the donor of the organ was HCV nucleic acid amplifications technology (NAT) positive or negative. In the NAT positive arm, the recipients will receive a course of direct acting antivirals (DAA) to begin on the day of transplant. If the donor was HCV antibody (Ab) positive and NAT negative, the recipients will receive close monitoring with serial HCV viral loads (VL) and will only begin treatment with DAA if they develop HCV viremia."
        },
        "conditionsModule": {
            "conditions": [
                "Hepatitis C",
                "Awaiting Organ Transplant"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 148,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "HCV NAT Positive Donor",
                    "type": "EXPERIMENTAL",
                    "description": "Intervention: 2 week treatment course with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily\n\nParticipants who receive allografts from a donor who is HCV NAT positive will receive treatment with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily, beginning on the day of transplant.",
                    "interventionNames": [
                        "Drug: Sofosbuvir/velpatasvir"
                    ]
                },
                {
                    "label": "HCV NAT Negative, HCV Ab Positive Donor",
                    "type": "EXPERIMENTAL",
                    "description": "Intervention: HCV viral load monitoring\n\nParticipants who receive allografts from a donor who is HCV Ab positive and NAT negative will have close serial HCV viral load monitoring and will be treated with a direct acting antiviral, 400mg / velpatasvir 100mg daily, for 6 weeks if HCV viremia develops.",
                    "interventionNames": [
                        "Drug: Sofosbuvir/velpatasvir",
                        "Other: Monitoring"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Sofosbuvir/velpatasvir",
                    "description": "2 weeks of treatment beginning on the day of transplant",
                    "armGroupLabels": [
                        "HCV NAT Negative, HCV Ab Positive Donor",
                        "HCV NAT Positive Donor"
                    ],
                    "otherNames": [
                        "Epclusa"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Monitoring",
                    "description": "Close HCV viral load monitoring Will receive direct acting antiviral treatment with 6 weeks of sofosbuvir/velpatasvir if the recipient develops HCV viremia during the post-transplant HCV viral load testing",
                    "armGroupLabels": [
                        "HCV NAT Negative, HCV Ab Positive Donor"
                    ],
                    "otherNames": [
                        "Sofosbuvir/velpatasvir (Epclusa)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Graft survival",
                    "description": "Functioning allograft not requiring mechanical support",
                    "timeFrame": "6 months post-transplant"
                },
                {
                    "measure": "HCV status of the transplant recipient",
                    "description": "Sustained virologic response (SVR) 12 weeks after HCV treatment completion in Arm A or at 6 months in Arm B (SVR defined as HCV RNA \\< lower limit of quantification)",
                    "timeFrame": "6 months post-transplant"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Treatment related adverse events",
                    "description": "Number of treatment related adverse events per patient using direct-acting antiviral HCV regimens in post transplant recipients",
                    "timeFrame": "6 months post-transplant"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Men and women who are age \u2265 18 years\n* Active on either the cardiac, lung, or kidney transplant waiting list\n* Willing and able to provide written informed consent to receive organs from an increased risk donor with a known transmissible infection\n\nExclusion Criteria:\n\n* Hepatitis B NAT or viral load positive\n* Evidence of cirrhosis or clinically significant liver disease",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Ann Woolley, MD",
                    "role": "CONTACT",
                    "phone": "617-732-5500",
                    "email": "awoolley@bwh.harvard.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Lindsey Baden, MD",
                    "affiliation": "Brigham and Women's Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Brigham and Women's Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ann Woolley, MD",
                            "role": "CONTACT",
                            "phone": "617-525-8418",
                            "email": "awoolley@partners.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "30946553",
                    "type": "DERIVED",
                    "citation": "Woolley AE, Singh SK, Goldberg HJ, Mallidi HR, Givertz MM, Mehra MR, Coppolino A, Kusztos AE, Johnson ME, Chen K, Haddad EA, Fanikos J, Harrington DP, Camp PC, Baden LR; DONATE HCV Trial Team. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. N Engl J Med. 2019 Apr 25;380(17):1606-1617. doi: 10.1056/NEJMoa1812406. Epub 2019 Apr 3."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006506",
                    "term": "Hepatitis A"
                },
                {
                    "id": "D000006526",
                    "term": "Hepatitis C"
                },
                {
                    "id": "D000006505",
                    "term": "Hepatitis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000006525",
                    "term": "Hepatitis, Viral, Human"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000004769",
                    "term": "Enterovirus Infections"
                },
                {
                    "id": "D000010850",
                    "term": "Picornaviridae Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                },
                {
                    "id": "D000086982",
                    "term": "Blood-Borne Infections"
                },
                {
                    "id": "D000003141",
                    "term": "Communicable Diseases"
                },
                {
                    "id": "D000018178",
                    "term": "Flaviviridae Infections"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9592",
                    "name": "Hepatitis A",
                    "asFound": "Hepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9591",
                    "name": "Hepatitis",
                    "asFound": "Hepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9611",
                    "name": "Hepatitis C",
                    "asFound": "Hepatitis C",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9610",
                    "name": "Hepatitis, Viral, Human",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7930",
                    "name": "Enterovirus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M13745",
                    "name": "Picornaviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M2593",
                    "name": "Blood-Borne Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M20324",
                    "name": "Flaviviridae Infections",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069474",
                    "term": "Sofosbuvir"
                },
                {
                    "id": "C000611331",
                    "term": "Sofosbuvir-velpatasvir drug combination"
                },
                {
                    "id": "C000604171",
                    "term": "Velpatasvir"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M341417",
                    "name": "Sofosbuvir-velpatasvir drug combination",
                    "asFound": "Conception",
                    "relevance": "HIGH"
                },
                {
                    "id": "M443",
                    "name": "Sofosbuvir",
                    "asFound": "His",
                    "relevance": "HIGH"
                },
                {
                    "id": "M349587",
                    "name": "Velpatasvir",
                    "asFound": "Complement",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}